Phosphorylation of ribavirin and viramidine by adenosine kinase and cytosolic 5′-nucleotidase II:: Implications for ribavirin metabolism in erythrocytes

被引:41
作者
Wu, JZ [1 ]
Larson, G [1 ]
Walker, H [1 ]
Shim, JH [1 ]
Hong, Z [1 ]
机构
[1] Valeant Pharmaceut Int, Drug Discovery, Costa Mesa, CA 92626 USA
关键词
D O I
10.1128/AAC.49.6.2164-2171.2005
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Many nucleoside analog drugs, such as ribavirin and viramidine, are activated or metabolized in vivo through 5 '-phosphorylation. In this report, we determined the steady-state kinetic parameters for 5 '-monophosphorylation of ribavirin and viramidine by adenosine kinase. The apparent K-m for ribavirin is 540 mu M, and k(cat) is 1.8 min(-1). Its catalytic efficiency of 3.3 x 10(-3) min(-1) (.) mu M is 1,200-fold lower than that of adenosine. In contrast to the common belief that ribavirin is exclusively phosphorylated by adenosine kinase, cytosolic 5 '-nucleotidase II was found to catalyze ribavirin phosphorylation in vitro. The reaction is optimally stimulated by the physiological concentration of ATP or 2,3-bisphosphoglycerate. In phosphate-buffered saline plus ATP and 2,3-bisphosphoglycerate, the apparent K-m for ribavirin is 88 mu M, and k(cat) is 4.0 min(-1). These findings suggest that cytosolic 5 '-nucleotidase II may be involved in ribavirin phosphorylation in vivo. Like ribavirin, viramidine was found to be phosphorylated by either adenosine kinase or cytosolic 5 '-nucleotidase II, albeit with a much lower activity. The catalytic efficiency for viramidine phosphorylation is 10- to 330-fold lower than that of ribavirin, suggesting that other nucleoside kinase(s) may be involved in viramidine phosphorylation in vivo. Both ribavirin and viramidine are not phosphorylated by deoxycytidine kinase and uridine-cytidine kinase. The coincidence of presence of high concentrated 2,3-bisphosphoglycerate in erythrocytes suggests that cytosolic 5 '-nucleotidase II could play an important role in phosphorylating ribavirin and contribute to anabolism of ribavirin triphosphate in erythrocytes. Elucidation of ribavirin and viramidine phosphorylation mechanism should shed light on their in vivo metabolism, especially the ribavirin-induced hemolytic anemia in erythrocytes.
引用
收藏
页码:2164 / 2171
页数:8
相关论文
共 39 条
[1]   Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections [J].
Baker, R ;
Bray, M ;
Huggins, JW .
ANTIVIRAL RESEARCH, 2003, 57 (1-2) :13-23
[2]   Metabolism in human cells of the D and L enantiomers of the carbocyclic analog of 2′-deoxyguanosine:: Substrate activity with deoxycytidine kinase, mitochondrial deoxyguanosine kinase, and 5′-nucleotidase [J].
Bennett, LL ;
Allan, PW ;
Arnett, G ;
Shealy, YF ;
Shewach, DS ;
Mason, WS ;
Fourel, I ;
Parker, WB .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (05) :1045-1051
[3]   Mammalian 5′-nucleotidases [J].
Bianchi, V ;
Spychala, J .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (47) :46195-46198
[4]   STIMULATION BY GLYCERATE 2,3-BISPHOSPHATE - A COMMON PROPERTY OF CYTOSOLIC IMP-GMP 5'-NUCLEOTIDASE IN RAT AND HUMAN-TISSUES [J].
BONTEMPS, F ;
VINCENT, MF ;
VANDENBERGH, F ;
VANWAEG, G ;
VANDENBERGHE, G .
BIOCHIMICA ET BIOPHYSICA ACTA, 1989, 997 (1-2) :131-134
[5]   The broad spectrum antiviral nucleoside ribavirin as a substrate for a viral RNA capping enzyme [J].
Bougie, I ;
Bisaillon, M .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (21) :22124-22130
[6]   BISPHOSPHORYLATED METABOLITES OF GLYCERATE, GLUCOSE, AND FRUCTOSE - FUNCTIONS, METABOLISM AND MOLECULAR PATHOLOGY [J].
CARRERAS, J ;
BARTRONS, R ;
CLIMENT, F ;
CUSSO, R .
CLINICAL BIOCHEMISTRY, 1986, 19 (06) :348-358
[7]   The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen [J].
Crotty, S ;
Maag, D ;
Arnold, JJ ;
Zhong, WD ;
Lau, JYN ;
Hong, Z ;
Andino, R ;
Cameron, CE .
NATURE MEDICINE, 2000, 6 (12) :1375-1379
[8]   Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: Role of membrane oxidative damage [J].
De Franceschi, L ;
Fattovich, G ;
Turrini, F ;
Ayi, K ;
Brugnara, C ;
Manzato, F ;
Noventa, F ;
Stanzial, AM ;
Solero, P ;
Corrocher, R .
HEPATOLOGY, 2000, 31 (04) :997-1004
[9]  
FRIDLAND A, 1986, CANCER RES, V46, P532
[10]   Side effects of therapy of hepatitis C and their management [J].
Fried, MW .
HEPATOLOGY, 2002, 36 (05) :S237-S244